AptarGroup, Inc. Q1 2026 Earnings Recap

ATR Q1 2026 May 4, 2026

Get alerts when ATR reports next quarter

Shares fell 2.5% following earnings as investors digested a deceleration in emergency medicine dispensing systems, which negatively impacted core sales by 3%, signaling weakness in a key segment despite growth in other areas.

Earnings Per Share Beat

$1.19 vs $1.15 est.

+3.5% surprise

Revenue Beat

982868000 vs 955951300 est.

+2.8% surprise

Market Reaction

1-Day +1.19%

5-Day -0.53%

30-Day -3.94%

See ATR alongside your other holdings

Add to your portfolio — free

Key Takeaways

Core sales declined 3% due to anticipated destocking in emergency medicine dispensing systems following exceptional prior growth.
Pharma segment showed strength in GLP-1 biologics, systemic nasal drug delivery, nasal decongestants, and ophthalmic dispensing.
Consumer dispensing benefited from volume and mix improvements in beauty and closures, though lower resin pricing pressured margins.
Several new product approvals and launches broaden growth platforms, including injectables and nasal delivery technologies.
Management emphasized disciplined execution and operational resilience amid a mixed operating environment.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit ATR on AllInvestView.